Is Johnson & Johnson a Good COVID Stock to Buy?
Johnson & Johnson (NYSE: JNJ) quickly emerged as a frontrunner in the early days of the coronavirus vaccine race. But with the vast commercial success of the vaccines developed by rivals Moderna and Pfizer, and the manufacturing delays that Johnson & Johnson faced earlier in the year that significantly hindered its distribution efforts, is the company still a long-term winner in the coronavirus vaccine space?
In this segment of Backstage Pass, recorded on Oct. 19, Fool contributors Rachel Warren and Brian Withers discuss this question, the company's most recent earnings report, and more.
Source Fool.com
